Lead Product(s): Lucid-201
Therapeutic Area: Psychiatry/Psychology Product Name: Lucid-201
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: FSD Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 25, 2021
The acquisition of Lucid illustrates FSD Pharma’s vision to build a portfolio of biotechnology assets on a new frontier of medicine that hold the potential to treat mental health disorders and neurodegenerative diseases in a new way including Lucid's pipeline, Lucid-201.